In this MasterClass, Dr. McGee discusses the identification and treatment of dry eye flares. By the end of this class, you will learn how to talk to patients about dry eye flares and how to manage them.
This activity is supported by an unrestricted educational grant from Kala Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
Sponsored by 
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 124261, is accredited by COPE for continuing education for optometrists for 0.25 hours.
Course #: 78863-TD
Activity #: 124261
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Selina R. McGee, OD, FAAO, Dipl ABO
Intrepid Eye Society Vice-President
Oklahoma Association of Optometric Physicians-Past President
Founder/CEO, BeSpoke Vision
Edmond, OK
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Selina R. McGee, OD, FAAO, Dipl ABO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Bruder, Cynosure, Dompé, Horizon Therapeutics, Kala Pharmaceuticals, Lumenis, Novartis, Optovue, Osmotica Pharmaceuticals, Science Based Health, Sun Pharmaceuticals, Tarsus, Thea, and Versant. Speaker's Bureau: Allergan, Dompé, Lumenis, and Optovue.
Evolve and The Fundingsland Group staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Kala Pharmaceuticals.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Christina Y. Weng, MD, MBA, FASRS
Mark T. Dunbar, OD, FAAO
David A. Eichenbaum, MD, FAAO
Jaclyn Garlich, OD, FAAO
Mohammad R. Rafieetary, OD, FAAO, FORS, ABO
John Kitchens, MD
Sara LeMay, OD
Sunir J. Garg, MD, FACS, FASRS
Charles C. Wykoff, MD, PhD, FACS
Sunir J. Garg, MD, FACS, FASRS
Charles C. Wykoff, MD, PhD, FACS
